Drug intelligence / Profile preview

4FLUART

Development stage: Phase 1
Lead developer: Fluart Innovative Vaccines
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

4FLUART is an inactivated, adjuvanted, whole virion quadrivalent influenza vaccine (QIV) developed by Fluart Innovative Vaccine Ltd, Hungary. It is designed to provide protection against influenza by stimulating the immune system. The vaccine is administered intradermally and is currently being evaluated for its safe usability and immunogenicity in adult subjects.

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on 4FLUART.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4FLUART.

Explore the full profile